Mycobacterial diseases often require prolonged therapy with multidrug regimens. Fluoroquinolones have excellent bactericidal activity against many mycobacteria; achieve effective serum, tissue, and intracellular levels following oral administration; and produce few adverse effects. These properties have led to the increasing use of fluoroquinolones for the treatment of mycobacterial infections. We reviewed clinical studies and reports involving the use of fluoroquinolones for mycobacterial diseases. Ofloxacin, ciprofloxacin, sparfloxacin, and pefloxacin exhibit clinical efficacy against mycobacterial diseases, especially tuberculosis and leprosy. Fluoroquinolones have generally been administered in regimens that include other agents. However, when a fluoroquinolone has been found to be the sole active agent in a multidrug regimen, the ready emergence of resistance to fluoroquinolones has been recognized, just as when they have been used as monotherapy. Therefore, to forestall the emergence of resistance to fluoroquinolones during the treatment of mycobacterial diseases, these drugs should always be used in combination with at least one other active agent, and they should be used only when effective alternative drugs are not available.
Mycobacterial diseases often require prolonged therapy with multidrug regimens. Fluoroquinolones have excellent bactericidal activity against many mycobacteria; achieve effective serum, tissue, and intracellular levels following oral administration; and produce few adverse effects. These properties have led to the increasing use of fluoroquinolones for the treatment of mycobacterial infections. We reviewed clinical studies and reports involving the use of fluoroquinolones for mycobacterial diseases. Ofloxacin, ciprofloxacin, sparfloxacin, and pefloxacin exhibit clinical efficacy against mycobacterial diseases, especially tuberculosis and leprosy. Fluoroquinolones have generally been administered in regimens that include other agents. However, when a fluoroquinolone has been found to be the sole active agent in a multidrug regimen, the ready emergence of resistance to fluoroquinolones has been recognized, just as when they have been used as monotherapy. Therefore, to forestall the emergence of resistance to fluoroquinolones during the treatment of mycobacterial diseases, these drugs should always be used in combination with at least one other active agent, and they should be used only when effective alternative drugs are not available.
Diseases caused by mycobacteria are often difficult to treat cin is generally the most potent fluoroquinolone against M. tuberculosis and other susceptible species; ciprofloxacin and require regimens containing several drugs administered over a prolonged period. Relatively few drugs are effective and ofloxacin, whose activities are roughly comparable, are the next most potent agents [2] . The incidence of mycobacterial against mycobacteria, especially Mycobacterium tuberculosis (in particular, the multidrug-resistant strains), Mycobacterium resistance to fluoroquinolones is relatively low at the present time [4] , and there are no reports of cross-resistance [5, 6] or leprae, and Mycobacterium avium complex. Hence, development of new classes of antimycobacterial agents is needed.
antagonism with other classes of antimycobacterial agents [7] . Fluoroquinolones can be administered orally with good abThe fluoroquinolones would appear to fulfill most of the criteria for an ideal class of antimycobacterial drugs. The in sorption, and favorable pharmacokinetics permit once-or twice-daily administration [8, 9] . Fluoroquinolones penetrate vitro activity of fluoroquinolones against mycobacteria and the efficacy of these drugs in murine models of mycobacterial extremely well into tissues and into host cells, such as macrophages, in which mycobacteria often reside [9] . The incidence infection have been documented in various studies and reviews [1 -3] . Fluoroquinolones have excellent bactericidal activity and severity of side effects of the fluoroquinolones are generally low [9, 10] . Furthermore, most of these drugs have minimal against several mycobacteria. Most strains of M. tuberculosis, M. leprae, Mycobacterium bovis, Mycobacterium kansasii, Myadverse interactions with other drugs [9, 10] , so they may be used for long-term therapy in combination with other antimycocobacterium marinum, and Mycobacterium xenopi are inhibited in vitro by concentrations of ciprofloxacin or ofloxacin ranging bacterial agents and with the diverse array of drugs that patients with HIV infection may be receiving. between 0.5 mg/L and 2.0 mg/L [1, 2] . Strains of M. avium complex are less susceptible to fluoroquinolones (MICs, 4 -Herein, we review the studies and clinical reports published through May 1996 that examine the clinical use of fluoroqui-ú16 mg/L), and almost all isolates of Mycobacterium chelonae are resistant to both ciprofloxacin and ofloxacin [2] . Sparfloxanolones in the treatment of various mycobacterial diseasesespecially tuberculosis, leprosy, and M. avium complex infections. regimen with activity against M. tuberculosis, so the patient effectively received quinolone monotherapy. For all of the clinical trials, either ciprofloxacin (500 -750 mg/d) or ofloxacin (300 -800 mg/d) has been used. In most of Data regarding the adverse effects of the long-term use of fluoroquinolones were available in some of the studies [10, the studies, fluoroquinolones have been used in combination with other antituberculosis agents [11, 13, 14, 16] ; however, 11 -13, 15] . In one study [10] , investigators compared adverse events associated with antituberculosis therapy in 153 patients in some instances, ciprofloxacin or ofloxacin was given alone [12, 15, 17] .
who received a regimen of either isoniazid, rifampin, pyrazinamide, and ethambutol or isoniazid, rifampin, and ciprofloxaWhen given as monotherapy, ciprofloxacin appears to have good early bactericidal activity, as demonstrated by the reduccin (HRC). In this report, Ç30% of patients in each group experienced an adverse event that was probably or possibly tion in cfu/mL of M. tuberculosis in sputum by day 7 of treatment [17] . However, when ofloxacin alone was used for longerdue to medications. Pruritic rash and athralgias were the most common adverse events in both groups. One patient in the term therapy, there was poor sterilization of sputum [11, 12, 15] , principally because of the ready emergence of resistance HRC group developed seizures and died. These seizures were suspected of being related to complications resulting from her to fluoroquinolones [11, 12] . The contribution of individual quinolones is difficult to assess in regimens that already include underlying HIV disease. Tremors, nausea, insomnia, flu-like symptoms, facial swelling, and crystalluria have also been reeither of the highly effective antituberculous agents, isoniazid or rifampin, in the treatment of patients infected with drugported in patients who received antituberculous drug regimens that included quinolones [10, 12, 13, 15] . Therapy was genersusceptible strains of M. tuberculosis [13, 14, 16 -18] . In trials that included isoniazid or rifampin, the quinolone-containing ally not discontinued [10, 12, 13, 15] . For these patients receiving multidrug regimens, it is difficult to determine which of regimens appeared to act more slowly and be less effective for sterilizing sputum than pyrazinamide-or ethambutol-conthese adverse events can be attributed specifically to a quinolone. taining regimens [17, 18] . When a fluoroquinolone was added to a regimen as a second-line agent to treat M. tuberculosis Recent outbreaks of multidrug-resistant tuberculosis have prompted the Centers for Disease Control and Prevention to infection resistant to a variety of drugs, the response was variable, most likely depending on susceptibilities to the other recommend that potential alternative regimens be used in the prophylactic treatment of contacts exposed to strains of drugs that were used [11 -13, 15] . The best response was noted with regimens that included rifampin [13] . Ofloxacin at a dose M. tuberculosis resistant to both isoniazid and rifampin [21] .
On the basis of in vitro studies mentioned previously [2], one of 800 mg/d appeared to be more effective than at a dose of 300 mg/d [12] .
of the proposed potential regimens includes either ofloxacin (400 mg twice daily) or ciprofloxacin (750 mg twice daily) in Isolates recovered after treatment from all nonresponders and most of the patients who relapsed demonstrated resistance combination with pyrazinamide (25 -30 mg/[kgrd]). Another suggested alternative regimen includes pyrazinamide and ethto fluoroquinolones [11, 12, 15] . Similarly, selection of fluoroquinolone resistance during therapy has been noted [5, 19] . In ambutol (15 -25 mg/[kgrd]). The suggested duration of continuous prophylactic therapy ranges from 6 months to 12 months. a recent report from New York City [20] , 22 patients were identified who were infected with strains of M. tuberculosis Conclusions. Most of the published reports on the use of fluoroquinolones in the treatment of tuberculosis have examresistant to ciprofloxacin or ofloxacin during the period 1991 -1993. All of these patients had been receiving a fluoroquinoined the role of ofloxacin or ciprofloxacin. Clearly these drugs have rapid bactericidal activity against M. tuberculosis, even lone for treatment of tuberculosis resistant to conventional antituberculous agents. Fluoroquinolone resistance had arisen in when used alone. However, monotherapy with a fluoroquinolone is very likely to result in failure or relapse, with the devel-16 patients when a fluoroquinolone was the only active agent in a multidrug regimen or the therapy was not directly superopment of resistance to all members of this drug class. Therefore, in most studies, a fluoroquinolone has been included in vised and compliance was poor. In that study, therapy with a fluoroquinolone was given for a median duration of 137 days a regimen consisting of other antimycobacterial drugs. Because of the results of these studies, the quinolones should not be (range, 43 -298 days) before the emergence of resistance was detected. Restriction fragment length polymorphism analysis used as first-line agents, but rather, they should be reserved for the treatment of tuberculosis that is resistant to both of the indicated that resistance had arisen independently in at least seven unrelated strains.
primary agents, isoniazid and rifampin. It is thus important to fully test such strains for susceptibility to a broad range of In another report of two cases of fluoroquinolone-resistant tuberculosis [6] , one patient had received several courses of antimycobacterial agents. Then, it may be possible to design a regimen that includes at least one other effective agent besides fluoroquinolones for presumed urinary tract infection that was eventually diagnosed as renal tuberculosis. The second patient the fluoroquinolone in order to forestall the emergence of resistance to fluoroquinolones. had received ciprofloxacin in a regimen for presumed M. avium / 9c3f$$no74 10-28-97 08:22:08 cida UC: CID Hence, it is difficult to assess the individual contribuinvolved patients with lepromatous leprosy who had not retion, if any, of the fluoroquinolones used. However, sparfloxaceived prior therapy. Pefloxacin (400 -800 mg/d) [22, 23] , cin has been evaluated as monotherapy in two reports. In an ofloxacin (600 mg/d) [23] , and sparfloxacin (200 mg/d) [24] open-label study [27] , 22 patients with AIDS and disseminated were used either alone [24] or as the initial agent, followed by M. avium complex infection were treated with sparfloxacin conventional World Health Organization -multidrug therapy (200 -400 mg/d) for 4 weeks. A decrease in cfu/mL of (WHO-MDT) that included rifampin, dapsone, and clofazimine M. avium complex in blood cultures was noted for seven of [22, 23] . These reports include limited numbers of patients, these patients. Four patients did not respond, and 11 had an and the tools for assessment of clinical and microbiological increase in cfu/mL. In a small randomized, double-blind study efficacy are not as refined as for M. tuberculosis or other rela- [28] of 19 patients with AIDS and disseminated M. avium tively easily culturable mycobacteria. The mouse footpad infeccomplex infection, sparfloxacin (400 mg on day 1, followed tivity assay has been generally regarded as the most reliable by 200 mg/d from day 2 to 10) was compared with placebo. laboratory indicator of the bactericidal activity of antileprotic No decrease in the cfu/mL in blood cultures was noted for agents.
either group between days 1 and 11. Clinical improvement was noted after 4 -8 weeks of fluoroOnly one randomized study has been conducted to examine quinolone monotherapy in all three studies [22 -24] . Each of a quinolone in a multidrug regimen in which rifampin, ethamthe three fluoroquinolones displayed good bactericidal activity, butol, and ciprofloxacin (750 mg/d) were compared with plaas determined with the use of the mouse footpad infectivity cebo [29] . After 8 weeks there was a §1 log decrease in cfu/ assay. Pefloxacin and ofloxacin were comparable in activity mL of M. avium complex in blood samples from four of nine [23] . No relapses were reported in any of the studies [22 -24] . treated patients, whereas no decrease was noted for 10 placebo Adverse effects that were noted included abdominal pain, recipients. However, no clinical improvement was noted. A athralgias, dizziness, and pruritus [22] ; nausea, diarrhea, and few nonrandomized studies have examined combination therelevation of alkaline phosphatase, bilirubin, and blood urea apy that included fluoroquinolones in patients with AIDS and nitrogen levels [23] ; and leg pain [24] . One patient developed disseminated M. avium complex infections. In one study, 15 mania, which was attributed to pefloxacin; the drug was withpatients were treated with amikacin, rifampin, ethambutol, and drawn, with subsequent regression of the symptoms [23] . No ciprofloxacin (750 mg twice daily) for 12 weeks [30] . A sigsignificant drug interaction was observed between pefloxacin nificant decrease was noted in the mean cfu/mL of M. avium or ofloxacin and the agents in the WHO-MDT regimen [23] .
complex in blood cultures, and clinical improvement was obConclusions. The fluoroquinolones appear to be quite acserved in all patients at 4 weeks. However, only three of eight tive, even as monotherapy, for the treatment of leprosy. As for pretreatment isolates that were tested were susceptible to ciother mycobacterial infections, these drugs are used in combiprofloxacin in vitro. nation with other active agents to forestall emergence of resisIn another small study [31] of four patients, clearance of tance. Such therapeutic use of fluoroquinolones, which are bac-M. avium complex bacteremia, with clinical improvement after tericidal for M. leprae, may help to reduce the total duration 8 weeks, was observed with a regimen of amikacin, rifampin, of therapy [25, 26] . Since there are so few active agents for the ethambutol, clofazimine, and ciprofloxacin (750 mg twice daily). treatment of leprosy, the emergence of resistance to dapsone, Similar results were noted in 12 patients when clarithromycin and rifampin, or clofazimine in M. leprae may necessitate the use amikacin were used together with ciprofloxacin (500 mg three of a fluoroquinolone. This situation is in contrast to that in times a day) [32] . In a multicenter trial [33] , 31 patients were the treatment of tuberculosis, for which a fluoroquinolone is treated for 12 weeks with rifampin, ethambutol, clofazimine, and necessary only for the (so far) rare cases in which the infecting ciprofloxacin (750 mg twice daily), and, in some instances, with strain is demonstrated to be resistant to most first-line antituberamikacin. There was a mean log 10 decrease in cfu/mL from 2.1 culous drugs.
to 0.7 at 4 weeks, together with clinical improvement. In most of these studies, bacteriologic and clinical improvement was sustained only as long as therapy was continued.
M. avium Complex
Conclusions. [37] , and dissemquently responded to therapy with ethambutol and ciprofloxacin. Ciprofloxacin has also been used in the treatment of infecinated disease [38] . Both ofloxacin (300 -1,000 mg/d) and ciprofloxacin (750 mg twice daily) have been used for durations tions with M. kansasii that was resistant to rifampin, isoniazid, and ethambutol and in patients who could not tolerate the of therapy ranging from 3 months to 12 months. Ofloxacin used alone was successful in the treatment of a patient with primary agents [44] . MICs of ciprofloxacin were §2 mg/L. Overall, sputum conversion was noted in 90% of cases, alpulmonary cavitary disease [37] and in three patients with sternotomy wound infections who also underwent surgical dethough the contribution of ciprofloxacin could not be ascertained, since response was not delineated separately for the bridement [34] . Monotherapy with ciprofloxacin [36] was successful in the treatment of six of seven patients with cutaneous ciprofloxacin-treated group. Mycobacterium haemophilum. M. haemophilum, a fastidiinfection due to M. fortuitum that was susceptible to ciprofloxacin. Three of these patients relapsed, and all of the posttreatous, slow-growing mycobacterial species that requires an ironsupplemented culture medium and a lower incubation temperament isolates from these patients were resistant to ciprofloxacin.
ture for growth than do other mycobacteria has rarely been reported to cause disease in immunosuppressed patients, espeFluoroquinolones have also been used in combination with other agents to treat M. fortuitum infections. Ofloxacin, in comcially those with AIDS. In a report of 13 cases of disseminated M. haemophilum infections [45], the MIC of ciprofloxacin for bination with amikacin and surgical debridement, was used successfully to treat sternotomy wound infections in nine of the isolates was 2 mg/L. Nine of the 13 patients received multiple drug regimens that included ciprofloxacin. The other agents 10 patients [35] , and a case of disseminated M. fortuitum infection was successfully treated with ciprofloxacin, sulfathiazole, that were used included isoniazid, rifampin, ethambutol, clarithromycin, amikacin, clofazimine, minocycline, and doxycyand minocycline [37] .
Conclusions. The published experience on the use of flucline. The infections resolved in seven of these nine patients, although the individual contribution of ciprofloxacin could not oroquinolones for the treatment of M. fortuitum infections is very limited. These drugs appear to have some efficacy when be determined. Combination therapy with rifampin, doxycycline, and ciprofloxacin was also successful in the treatment of used alone, though surgical debridement and other antimicrobial agents are likely to form the mainstay of therapy. Relapse another patient with disseminated M. haemophilum infection [46] . due to emergence of resistance occurs when fluoroquinolones are used as monotherapy.
Mycobacterium genavense. A recent report [47] described 54 patients with infections due to M. genavense, a newly recognized fastidious pathogen that does not grow on conventional Other Mycobacterial Infections solid media and is identified by PCR amplification and sequencing of DNA fragments encoding segments of 16S RNA. All Fluoroquinolones have also been used to treat other mycobacterial infections. The literature consists of either case reports cases occurred in patients with advanced HIV infection, and symptoms and signs of disseminated disease were similar to or clinical studies that have included fluoroquinolones -primarily ciprofloxacin -in combination with a variety of other those in AIDS patients with disseminated M. avium complex infection. Forty-one patients received some form of treatment antimicrobial agents for the treatment of these infections. These studies have not specifically addressed the role of fluoroquinofor the infection. Twenty-one (51%) of these 41 patients received treatment with regimens that included ciprofloxacin. lones in the response to therapy; hence, no definite conclusions can be drawn as to the clinical efficacy of fluoroquinolones in
The other drugs included in these regimens were isoniazid, rifampin, ethambutol, clofazimine, clarithomycin, amikacin, the treatment of these diseases.
M. chelonae. There have been only scattered case reports pyrazinamide, and rifabutin. No details were available regarding the specific responses to therapy for those patients who on the use of fluoroquinolones to treat infections with M. chelonae, an organism that has been relatively resistant to these received ciprofloxacin-containing regimens. However, the overall median survival was 263 days for patients who received agents in vitro. Ciprofloxacin has been used in combination with a macrolide and an aminoglycoside to successfully treat at least two drugs for at least 1 month, as compared with 81 days for the untreated group ( P Å .0009 
